Your browser doesn't support javascript.
A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage.
Ishay, Yuval; Potruch, Assaf; Schwartz, Asaf; Berg, Marc; Jamil, Khurram; Agus, Samuel; Ilan, Yaron.
  • Ishay Y; Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel. Electronic address: hawkempire@gmail.com.
  • Potruch A; Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel. Electronic address: poassaf@gmail.com.
  • Schwartz A; Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel. Electronic address: sch.asaf@gmail.com.
  • Berg M; Altus Care powered by Oberon Sciences, Denmark, Israel; Department of Pediatrics, Lucile Packard Children's Hospital, Stanford, USA. Electronic address: marc@area9.dk.
  • Jamil K; Altus Care powered by Oberon Sciences, Denmark, Israel. Electronic address: khurram@area9.dk.
  • Agus S; Altus Care powered by Oberon Sciences, Denmark, Israel. Electronic address: samugus2@gmail.com.
  • Ilan Y; Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel. Electronic address: ilan@hadassah.org.il.
Biomed Pharmacother ; 143: 112228, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1432983
ABSTRACT
Coronavirus disease 2019 (COVID-19), which is a respiratory illness associated with high mortality, has been classified as a pandemic. The major obstacles for the clinicians to contain the disease are limited information availability, difficulty in disease diagnosis, predicting disease prognosis, and lack of disease monitoring tools. Additionally, the lack of valid therapies has further contributed to the difficulties in containing the pandemic. Recent studies have reported that the dysregulation of the immune system leads to an ineffective antiviral response and promotes pathological immune response, which manifests as ARDS, myocarditis, and hepatitis. In this study, a novel platform has been described for disseminating information to physicians for the diagnosis and monitoring of patients with COVID-19. An adjuvant approach using compounds that can potentiate antiviral immune response and mitigate COVID-19-induced immune-mediated target organ damage has been presented. A prolonged beneficial effect is achieved by implementing algorithm-based individualized variability measures in the treatment regimen.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Medical Informatics / Chemotherapy, Adjuvant / COVID-19 / COVID-19 Drug Treatment Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Medical Informatics / Chemotherapy, Adjuvant / COVID-19 / COVID-19 Drug Treatment Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2021 Document Type: Article